At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 78 enrolled
Drug / intervention
Riluzole +1 moredrug
Likely dose
Riluzole 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Investigation of the Efficacy in Childhood Obsessive-Compulsive Disorder of Riluzole: An Antiglutamatergic Agent
In Brief
A Phase 2 clinical trial evaluating Riluzole and Placebo for Obsessive-Compulsive Disorder and 4 related conditions. Completed, enrolled 78 participants across 1 site.
Detailed Summary
This study will examine the effectiveness of riluzole for treating Obsessive-Compulsive Disorder in Youth, Including those with Autism Spectrum Disorders.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObsessive-Compulsive Disorder, Autism Spectrum Disorder, Autism, Asperger Disorder, Developmental Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2005
First PostedNov 2005
Primary CompletionFeb 2012
TodayJul 2026
First PostedNov 9, 2005
Enrollment StartAug 1, 2005
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 20.6 years ago
Interventions
Riluzoledrug
Active drug put into 10-mg capsules by NIH Clinical Center Pharmacy. Matched placebo capsules were also prepared by NIH Clinical Center Pharmacy. Dose up to 120 mg daily, divided into bid dosages.
Placebodrug
Capsules matched active drug in appearance.